• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection

    2020-09-18 13:30:36
    World Journal of Stem Cells 2020年8期
    關鍵詞:裁量知識產權

    Panagiotis Mallis,Efstathios Michalopoulos,Theofanis Chatzistamatiou,Catherine Stavropoulos-Giokas,Hellenic Cord Blood Bank,Biomedical Research Foundation Academy of Athens,Athens 11527,Greece

    Abstract

    Key words:SARS-CoV-2;COVID-19;Respiratory syndrome;Cytokine storm;Mesenchymal stromal cells;Immunoregulation;Lungs;Th2 response;Dendritic cells;Natural killer cells

    INTRODUCTION

    In December 2019,a new highly transmitted coronavirus,which was provisionally named 2019-novel coronavirus,was spread in Wuhan,China[1].In March 2020,the International Committee on Taxonomy of Viruses (ICTV) has renamed it as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)[2].The zoonotic transmission in a seafood market of Wuhan is speculated until now as the initial route of transmission to humans[2,3].By the time that this publication is prepared,more than 7258842 cases have been reported,and more than 411879 deaths have been occurred worldwide.Due to the global transmission of SARS-CoV-2,the World Health Organization recognized it as a serious public health issue and in January 2020 declared coronavirus disease-19 (COVID-19) as pandemic[1].Despite the fact that China was initially affected by COVID-19,accounting more than 80000 cases and 77000 deaths,the United States is now the leading country in confirmed SARS-CoV-2 cases[4].It is estimated that more than 1979893 people have been infected in the United States[4].The European Union,Italy,and Spain have been stricken hard by COVID-19,accounting for more than 32500 deaths[4].

    Epidemiological studies have shown that SARS-CoV-2 infection and disease severity vary between the two genders.Currently,it has been reported that males are more susceptible to COVID-19 infection than females[5,6].In addition,SARS-CoV-2 can affect all group ages,while 15% of patients may suffer from the severe form of this disorder[3].Moreover,the probability for severe disorder occurrence increases dramatically in those aged over 65 years[3,5,7].The average mortality of COVID-19 is under 3%,however,in highly affected countries such as Italy,Spain and France,the mortality rate may exceed 6%[4].Additionally,mortality rate can be varied and is dependent on underlying disease and age[3].Recently,a mortality rate of 10%-27% was reported in patients aged over 85 years,3%-11% in ages of 65-84 years,1%-3% in ages of 55-64 years,and below 1% in ages of 20-54 years[3,5,7].

    SARS-CoV-2 is responsible for inducing severe acute respiratory distress syndrome(ARDS) in infected patients,which promotes further lung damage and tissue fibrosis[8,9].Its pathophysiology is related with elevated levels of inflammatory cytokines such as IL-2,IL-6,IL-7,GSCF,IP10,MCP1,MIP1A,and TNF-α,an event which is known as “cytokine storm”[9-11].Except for lung damage,SARS-CoV-2 may infiltrate other organs such as heart,kidney,and brain,causing cardiomyopathy,arrhythmias,kidney failure,and encephalitis,respectively[3,12,13].Also,the placental transmission of SARS-CoV-2 from mothers to their fetuses is currently being investigated[13,14].In the study of Schwartz[13],no SARS-CoV-2 intrauterine transmission from infected mothers to their fetuses was reported.Additionally,no maternal deaths from SARS-CoV-2 has been reported to date,which is in contrast to previous related viruses such as SARS and Middle East respiratory syndrome (MERS)[13-15].

    Until now,several treatments have been tested,including prophylactic hydroxychloroquine and colchicine administration,antiviral agents,monoclonal antibodies against SARS-CoV-2,and transfusion of convalescent plasma[16-19].The majority of the above treatments have Food and Drug Administration (FDA) approval for their application to other diseases,while their use in COVID-19 patients is still under investigation.Remdesivir,an experimental drug to treat Ebola,has been tested in clinical trials for its efficacy in SARS-CoV-2 infection,while globally a great effort has been performed for the production of satisfactory vaccines against the current virus[19-24].Recently,remdesivir was approved by the FDA for application in COVID-19 patients.

    Knowing that COVID-19 can cause significant modifications to the patient’s immune system,alternative strategies should also be tested.In this way,the mesenchymal stromal cells (MSCs),a mesodermal cellular population originated mostly from bone marrow (BM),Wharton’s Jelly tissue (WJ-tissue),and adipose tissue(AT),could be potentially applied in COVID-19 patients[25-28].MSCs are known for their immunoregulatory/immunosuppressive properties,which are exerted in several ways[25].MSCs are currently applied in severe autoimmune disorders such as multiple sclerosis (MS),amyotrophic lateral sclerosis (ALS),Crohn’s disease,diabetes mellitus,etc.,thus reducing disease manifestations[29].In this way,MSCs can be applied mostly as cotherapy in combination with the above pharmaceutical agents to reverse the severe manifestations induced by SARS-CoV-2 infections.In this review,we will highlight the specific immunomodulation aspects of MSCs and their potential application in patients infected by SARS-CoV-2.Furthermore,the immune response against COVID-19,MSCs origin,immunoregulatory properties,and their possible application in COVID-19 will be presented.For the purposes of the current review article,we searched initially over 300 published articles focused on COVID-19 pathogenesis and MSC biology.During the eligibility process,166 studies were excluded and the remaining 134 articles were finally included in this review.Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram describes the methodological framework that was followed in the current article (Supplementary Figure1).Based on the above data,the scientific community might consider the broad use of MSCs in critically ill patients,improving their overall condition.

    INVASION MECHANISM OF SARS-COV-2

    SARS-CoV-2,according to the ICTV,is placed within theCoronaviridaeand specifically is a member of the subgenusSarbecovirus[2,30].SARS-CoV-2 consists of four structural proteins,spike (S),envelope (E),membrane (M),and nucleocapsid (N),and its diameter is approximately 50-150 nm[31,32].It is a positive-sense single-stranded RNA virus (++ssRNA),while its genome contains 29903 bases[33].The use of molecular methods has revealed that SARS-CoV-2 (Genbank accession No.NC_045512) is similar to bat -SL-CoVZC45 (88% similarity,Genbank accession No.MG772933.1) and bat-SLCoVZXC21 (89% similarity,Genbank accession No.MG772934.1)[33-35].Also,it is related more with the original SARS-CoV (80% similarity,Genbank accession No.FJ588686)than the MERS coronavirus (MERS-CoV,50% similarity,Genbank accession No.NC_019843)[36].

    The infection of SARS-CoV-2 begins with its proper adaption to the angiotensin I converting enzyme 2 receptor (ACE2),a process where the S protein is involved[17].Zhouet al[37]showed with the use of reverse genetics that ACE2 is the main receptor that SARS-CoV-2 uses for its fusion with the cellular membrane.Moreover,Wrappet al[38,39]showed that SARS-CoV-2 can bind ACE2 with higher affinity than the original SARS-CoV.Furthermore,the entrance of the virus to host cells is performed by the S protein primed by transmembrane protease serine 2 (TMPRSS2)[40].TMPRSS2 is a cysteine-rich protease domain,and its expression is regulated by androgenic hormones[41].Overexpression of TMPRSS2 is mostly observed in prostate cancer[41].Its relation with the pathophysiological mechanism of SARS-Cov-2 led researchers to associate possibly its function with lung damage severity and tumorigenesis.

    ACE2 and TMPRSS2 are mostly found in alveolar type II cells[42].Additionally,capillary endothelial cells (ECs) of other tissues such as heart,liver,kidney,and intestine also express the above proteins[43].For this reason,patients suffering from COVID-19,besides pneumonia,which is the most common manifestation,may exhibit other disorders such as cardiomyopathy,impaired liver and kidney function,and encephalitis.

    IMMUNE SYSTEM AND COVID-19

    After the infiltration of SARS-CoV-2 to the host cells,a specific series of events occur.COVID-19 is characterized by three-phase immunopathology,where the patient’s immune system has a central role.Among patients,fever (92.8% of the patients),cough(69.8%),dyspnea (34.5%),myalgia (27%),headache (7%),and diarrhea (6%) were the most common symptoms[3].Additionally,there is an increasing tendency that younger persons (ages <20-years-old) can be asymptomatic carriers of SARS-CoV-2,who can transmit effectively the virus to others[5,7].

    The first phase is the incubation – non-severe stage,where the virus is recognized by the immune system[5,44].In this way,the innate immune response is performed to limit the virus infection.If the virus escapes the host’s defense,then the second phase is initiated[44,45].For this reason,immunocompromised patients or patients with underlying disorders characterized by impaired immune function,may have increased probabilities for severe disease occurrence.Chenet al[5]showed that the most common underlying diseases,which were related with the severe outcome,were cardiovascular disease,hypertension,and diabetes mellitus.

    In the second phase,the virus induces severe damage to the infected cells through its replication cycle[46].This event leads to the activation of dendritic cells (DCs),epithelial cells,and macrophages,which are producing IL-1β,IL-2,IL-6,IL-8,interferon (IFN)-α/β,TNF-α,C-C motif chemokine 3 (CCL3),CCL5,CCL2,and IP-10.These inflammatory molecules can efficiently stimulate T helper cell (Th)1,Th2,and Th17 responses.Indeed,the overactivation of CXCR3+CD4+T cells,CXCR3+CD8+T cells,and CXCR3+natural killer (NK) cells has been observed in COVID-19[47].These cells are responsible for the production of inflammatory cytokines.Previous studies in COVID-19 patients have shown increased levels of IL-1B,IL-1RA,IL-7,IL-8,IL-9,fibroblast growth factor,granulocyte-macrophage colony-stimulating factor (GMCSF),IFN-γ,G-CSF,IP10,MCP1,MIP1A,platelet-derived growth factor (PDGF),TNFα,vascular endothelial growth factor (VEGF)[48].Among them,IL-2,IL-6,IL-7,G-CSF,IP10,MCP1,MIP1A,and TNF-α were significantly higher in severely conditioned patients[9-11,47,49].In addition,thrombocytopenia,lymphopenia,respiratory failure,pneumonitis,shock,and organ failure have been observed in COVID-19 patients[11].In addition,Wanet al[50]reported that COVID-19 patients were characterized by overactivated lymphocytes despite the occurred lymphocytopenia that was evident in the peripheral blood.This study showed that CD8+T cells were reduced at a percentage of 28.4% and 61.9% in mild and severe group patients,respectively.Also,NK cell reduction was evident in both groups (34.1% in mild,47.6% in severe)[50].These findings were accompanied by significantly high IL-6 levels in both mild and severe groups.Additionally,Xuet al[51]reported the substantial reduction of CD4+and CD8+T cells in peripheral blood of COVID-19 patients,although it appeared that lymphocytes were overactivated due to high expression of human leukocyte antigen DR-isotype(HLA-DR) (34.7%) in CD4+and CD38 (39.4%) in CD8+T cells[51].

    The third phase involves the prolonged lung damage that can cause severe ARDS.These patients must enter the intensive care unit (ICU),followed by connection to extracorporeal membrane oxygenation in order to survive[46].It has been reported in COVID-19 patients that hyaluronan (HA) is produced due to the “cytokine storm”,thus promoting pneumonia accompanied by pulmonary ground-glass opacity[52].Indeed,IL1 and TNF-α can strongly induce the HA production through overactivation of HA-synthase-2 of CD31+cells and lung alveolar epithelial cells.A series of studies showed that damaged lungs are infiltrated mostly by macrophages,monocytes,and giant cells,while few overactivated CD4+and CD8+T cells were present[52,53].Furthermore,inflammatory cytokines can activate fibroblasts,which in turn can overproduce collagen,promoting even more lung fibrosis[53,54].

    Currently,the satisfactory administration of COVID-19 is a great challenge.Th1 and Th2 responses are playing a central role in disease severity of SARS-CoV-2 in the same way as MERS-CoV and SARS-CoV.Moreover,from previous experience,it is known that most neutralizing antibodies are against the S and E proteins[11,55].However,the manufacturing of COVID-19 specific drugs and vaccines is still an ongoing process.Alternative strategies should also be tested for the suppression of the hyperacute immune response,which can lead to patient survival.To date,a great number of pharmaceutical agents,including antiviral agents,monoclonal antibodies against inflammatory cytokines,and convalescent plasma,are under investigation for COVID-19 (Table1).The majority of these agents have current FDA approval for other diseases,including treatment of hepatitis C and rheumatic disease,while they are under evaluation for the safety,tolerability,and efficacy in COVID-19 patients.Most of these pharmaceutical agents have specific targets (e.g.,S protein,IL-6R,and IL-6)but also are accompanied by adverse reactions.Moderate adverse effects may be observed in patients,including fever,headache,nausea,skin rash,diarrhea,and impairment of liver function.In addition to the use of pharmaceutical agents,it has been suggested that MSCs can effectively suppress the patient’s overactivated immune system by utilizing their immunoregulatory properties.MSCs have been used extensively in a wide number of registered clinical trials,supporting their tolerability,safety,and efficacy[56].No severe adverse reactions have been observed after MSCs infusion to patients.In this way,MSCs could be employed as an alternative therapeutic strategy or as cotherapy in severely conditioned COVID-19 patients.

    ORIGIN AND PROPERTIES OF MSCS

    MSCs,a mesodermal multipotent cellular population,can mostly be derived from BM,WJ-tissue,umbilical cord blood,AT,amniotic fluid (AF),and dental pulp[57].MSCs also have been isolated from solid organs such as the liver,lungs and kidney.Friedenstein,40 years ago,was the first to isolate a fibroblastic-like cell population from BM with plastic adherent and differentiation properties[58].In 2006,the International Society for Cellular Therapy (ISCT) provided the minimum criteria for the proper identification of MSCs[59].Based on ISCT,the following criteria must be fulfilled to define MSCs:(1)Spindle-shaped plastic adherent cells;(2) Expression of specific antigens.Specifically,positive expression (≥ 95%) of CD73,CD90,CD105,and low expression (≤ 2%) of CD34,CD45,CD11a,CD19 and HLA-DR;and (3) Mesodermal multilineage differentiation abilities towards “osteocytes”,“adipocytes”,and “chondrocytes”.

    Additionally,ISCT proposed the term “multipotent mesenchymal stromal cells” be used when this cellular population is applied in experimental approaches[59].In 2019,the ISCT’s MSC committee reported that “mesenchymal stromal cells” have specific secretory,immunomodulatory,and homing properties and are distinguished from“mesenchymal stem cells”,which have restricted properties focused on self-renewal and differentiation[60].

    Until date,BM is the most common source for MSCs isolation,estimating that MSCs represent 0.01%-0.001% of total nucleated cells[25].BM-MSCs are located to the abluminal surface of sinusoidal blood vessels in BM.These cells represent the stroma,where can efficiently regulate the differentiation of the resident hematopoietic stem cells (HSCs)[25].Specifically,MSCs support HSC differentiation through the expression of c-Kit,CXCR4,and Tie2.It has been shown in the literature that CXCR4/CXCL12,and CXCR7/CXCL12 interplay has a significant impact on the regulation of HSC homing and differentiation[61].Additionally,the Notch-Delta,Wnt,Shh signaling pathways have been reported to be involved in this differentiation process[61].

    Unlike BM harvesting,MSCs can be non-invasively isolated from other sources,including the umbilical cord’s WJ-tissue,a discarded material after gestation[62].In recent years,there is a tendency to use MSCs derived from the stromal vascular fraction (SVF) of liposuction aspirates or subcutaneous AT in regenerative medicine applications[63].Typically,MSCs represents 1%-10% of AT resident cells,making AT a greater source than BM.MSCs originated from AT are known as adipose derived stem cells or adipose derived MSCs (AD-MSCs) and exhibit similar immunophenotypic,differentiation potential and immunoregulatory properties as MSCs from other sources[63].

    MSCs have been used in a great number of approaches,including tissue engineering and regenerative medicine applications,graftvshost disease (GvHD),cotransplantation with HSCs,and administration of autoimmune disorders such as MS,ALS,and Crohn’s disease[64-66].MSCs can exert their functions through the production of cytokines,chemokines,exosomes,and miRNAs,which can act in a paracrine manner on targeted cellular populations[25].Moreover,MSCs have proven their regenerative properties when applied to injured lungs,liver,kidney,and heart[67].Recently,it is under evaluation the beneficial regenerative effect of MSCs in erectile dysfunction[68,69].MSCs,due to their plasticity,have been differentiated successfully to ECs,vascular smooth muscle cells,hepatocytes,insulin-producing cells,etc.Much effort has been put into the transdifferentiation of MSCs to ectodermal cell lineages,such as neurons,by utilizing the induced pluripotent stem cell technology[70].

    Table1 Most common therapeutic compounds used for the treatment of coronavirus disease-19

    MSCs are immune privileged cells,and thus can be used either allogeneically or autologously in large scale clinical trials.Most often,a great number of clinical grade MSCs is required,which has been proven a quite demanding task.In this way,the autologous isolation and expansion of MSCs in significant numbers may be hampered by an individual’s characteristics,such as age and disease severity.On the other hand,allogeneic pooled MSCs may be a better option for regenerative medicine approaches.Le Blancet al[71]have reported that MSCs expressed low levels of HLA class II intracellularly,which can be presented to their membrane surface after IFN-γ induction.However,MSCs do not express the costimulatory molecules B7-1,B7-2,CD40,and CD40L.Studies in non-human primates have revealed that MSCs escape T cell recognition and are well tolerated[71,72].Besides the above properties,MSCs have unique immunoregulatory properties.Specifically,there is evidence that MSCs have a role in the antigen presentation process and are actively involving in organism homeostasis[29].

    IMMUNOMODULATORY PROPERTIES OF MSCS

    Despite the therapeutic potential of MSCs in regenerative medicine applications,these cells have shown promising results in the regulation of immune responses[25,29].MSCs can act both in immune activation and immune suppression,depending on the microenvironment stimuli (Figure1).The significant immunoregulatory/immunosuppressive abilities of MSCs have been exploited for therapeutic applications in autoimmune disorders and GvHD[65,66].Taking into account that SARS-CoV-2 can induce significant alterations to innate and adaptive immune responses,leading to the“cytokine storm”,the transfusion of MSCs to COVID-19 patients may be beneficial.

    Figure1 Immunomodulatory properties of activated MSCs against overactivated immune cells during SARS-CoV-2 infection.MSCs efficiently suppress the immune responses through the secretion of soluble molecules or cell-cell contact interactions.MSCs have a broad effect on the immune responses exerted by macrophages,dendritic cells,natural killer cells,and T and B cells.SARS-CoV-2:Severe acute respiratory syndrome coronavirus-2;MSCs:Mesenchymal stromal cells;NK cells:Natural killer cells;NO:Nitric oxide;IDO:Indoleamine-2,3-dioxygenase;EVs:Extracellular vesicles.

    It has been described in the literature that MSCs can effectively modulate DC maturation,T cells (na?ve and effector T cells – Th1/ Th2/ Th17 cells),and NK cell responses[25,29].In the presence of low IFN-γ levels,MSCs can translocate the intracellular HLA class II to their membrane,thus playing a role in innate immunity.On the other hand,high IFN-γ levels can induce MSCs to exert their immunoregulatory properties,mostly through paracrine signaling pathways.In addition,there is evidence that MSCs under specific circumstances may act as antigenpresenting cells[25].The immunomodulation abilities of MSCs can be exerted by delivered soluble factors (cytokines,chemokines,growth factors,modulators of enzyme function),direct cell-cell contact,or a combination of those (Table2)[29].

    Interplay between MSCs and macrophages

    MSCs can effectively modulate the responses of neutrophils and macrophages.Both cells are playing central roles to the antigen presentation process to DCs,leading to specific immune responses by the cells of innate immunity[73].Macrophages are distinguished to M1 (classically activated) and M2 (alternatively activated)macrophages[29].M1 macrophages are responsible for pathogen phagocytosis and presentation of antigen epitopes to DCs.In this process,a set of inflammatory cytokines are produced by M1 macrophages,such as TNF-α,ΙL-1α/β,IL-6,and IL-12,thus activating and promoting Th1 responses.On the other hand,M2 macrophages promote Th2 responses and are considered immunosuppressive cells[74].These cells exhibit low expression of inflammatory cytokines and high production of antiinflammatory IL-10,which is associated with tissue remodeling,wound repair,and clearance of apoptotic cells[74].It has been reported that MSCs can modulate the M1/M2 macrophage phenotype through cell-cell or paracrine interactions[29,75].

    論侵害知識產權的裁量性判賠..............................徐聰穎 11.19

    Activation of MSCs with IFN-γ leads to the production of TNF-α,MCP1,and IL-1β,which can further promote the M1 macrophage phenotype.Alternatively,MSCs,through the expression of prostaglandin E2 (PGE2),can induce M2 macrophage phenotype switch[29].Further evidence for the role of MSCs in promoting the M2 macrophage phenotype arises from the study of Wahnonet al[76].Specifically,they reported that signal transducer activators of transcription-3 (STAT3) is activated through cell-cell interactions between MSCs and macrophages[76].Moreover,the same study showed that the STAT3 transcription factor is responsible for IL-10 production by macrophages and DCs,promoting further their immunosuppressive functions[76].

    Table2 Immunomodulation mechanisms of mesenchymal stromal cells

    Regulation of DC maturation

    Immature DCs (imDCs),the immune sentinels of the periphery,can be activated after inflammatory cytokine production by macrophages.Cleaved antigenic epitopes are loaded to HLA molecules of imDCs,followed by the presentation to T cells of the draining lymph nodes[77].Then,DCs undergo maturation,which can induce specific Th1 and Th2 responses against specific antigenic epitopes.It has been found that TNFα,IL-1β,and IL-6,produced either by M1 macrophages or IFN-γ activated MSCs,can drive DC maturation[78].The prevention of DC maturation is of great importance,especially when this leads to prolonged T cell responses,causing host cell and tissue damage.Several studies have shown that MSCs can interfere with DCs maturation through the production of soluble factors[29,78,79].Mostly,it has been suggested that secreted PGE2 by activated MSCs plays an important role in the inhibition of DCs maturation[29].This has been confirmed by results from co-culture studies using MSCs and DCs[80].These studies,were characterized by low expression of CD38,CD80,CD86,IL-6,and IL-12,which are significant molecules for T cell activation[81].Moreover,DCs exhibited low migratory ability,exerted by CCR7-CCL21 interaction.Liuet al[82]suggested that the production of TNF-α-stimulating gene 6 by MSCs can suppress DCs maturation though the inactivation of signaling cascades mediated by mitogen activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB).

    The inhibitory effect of MSCs in DC maturation can be increased by the production of specific miRNAs,including miR-21-5p,miR-142-3p,miR-223-3p,and miR-126-3p[83].In this process,extracellular vesicles (EVs) of MSCs are enriched with the above miRNAs,suggesting an additional way of regulating DC maturation[84].

    MSCs and T cell responses

    Immunomodulation of T cell responses can be exerted by MSCs in several ways.MSCs secrete a set of molecules that can act either positively or negatively to the T cell responses.Also,inhibition of T cell proliferation can be performedviacell-cell contact with MSCs[85].

    Dependent on the microenvironment stimuli,MSCs can effectively inhibit T cell proliferation through the production of PGE2,indoleamine-2,3-dioxygenase (IDO),TGF-β,and hepatocyte growth factor (HGF)[25,29].The effect of PGE2 inhibition of T cell proliferation was reported for the first time in 1971[86].Several years later,the specific mechanism of action by which PGE2 can exert its immunosuppressive effects on T cells was revealed.PGE2 is a prostanoid,which is synthesized by arachidonic acid through the action of cycloxygenase-1[87].PGE2 is responsible for the production of cAMP in activated T cells.CAMP plays a key role in the downregulation of IL-2 and IL-2R expression and abrogation of Ca2+after T cell receptor (TCR) activation.Also,PGE2 negatively regulates the hydrolysis of phosphatidylinositol and the production of diacylglycerol and inositol phosphate (IP),resulting in T cell inactivation[87].Recently,it was reported that PGE2 may be involved in T cell polarization,promoting further Th2 responses.In addition,PGE2 produced by MSCs can orchestrate the CD4+CD25+FOXP3 T reg responses,influencing even more the immunosuppression of hyperactivated T cells[29].

    IDO also is a strong immunosuppressive agent of T cell responses[85].Specifically,IDO blocks the metabolism of tryptophan to kynurenine in T cells.Kynurenine is an essential amino acid for the cell cycle of T cells,and its absence leads to G0/G1 cell cycle arrest.In addition,Ryanet al[88]reported that IFN-γ activated MSCs can produce TGF-β1 and HGF and,in combination with IDO,can significantly suppress alloreactive T cell proliferation.MSCsviathe secretion of nitric oxide (NO) can inhibit T cell proliferation[89].NO is another potent immunosuppressive agent that can effectively downregulate immune responses.Specifically,NO is responsible for the suppression of signal transducer and activator of transcription 5 phosphorylation,which further results in the inhibition of TCR-mediated T cell proliferation and inflammatory cytokine production.Additionally,it was found that galectins 1 and 3 secreted by MSCs can effectively suppress T cell proliferation by preventing TCR clustering through a crosslink interaction mechanism[89].

    Additionally,MSCs can exert their immunosuppressive properties through T cell apoptosis mediated by cell-cell interactions[90].In this way,the Fas/Fas ligand death signaling pathway can induce apoptosis to T cells,through downstream activation of Fas-associated death domain and caspases.It has been found that MSCs,upon inflammatory stimuli,can express the Fas ligand,binding in this way to Fas receptor of hyperactivated T cells[90,91].Another potential activator of Fas-associated death domain is the TNF-related apoptosis-inducing ligand (TRAIL)/death receptor (DR)signaling pathway.IFN-γ activated MSCs produce high amounts of TRAIL,which binds to DRs expressed in T cells,thus leading to their apoptosis.Also,MSCs can reduce T cell proliferationviaprogrammed death ligand-1 (PD-L1)/programmed death-1 (PD-1) interaction.Specifically,PD-L1 expressed by MSCs binds to the inhibitory checkpoint molecule PD-1 of T cells,followed by Src-homology 2 domaincontaining protein tyrosine phosphatases (SHP)-1 and SHP-2 phosphorylation.Finally,inhibition of MAPK is performed,which leads to inhibition of cellular proliferation.The PD-L1 can inhibit cellular proliferation and may have a broad effect on T cell subpopulations,including CD4+,CD8+,and Th17 cells[91].Remarkably,Luz-Crawfordet al[92]showed that the PD-L1/PD-1 interaction also could induce inhibition of Th17 cellsviacell-cell contact.On the other hand,this mechanism has a positive association with CD4+CD25+FOXP3 T reg proliferation.

    MSCs and B cell responses

    Similarly,to T cell modulation,B cell responses can be regulated by MSCsviathe secretion of soluble factors and through cell-cell contact interactions.IDO and PGE2 alongside the production of TGF-β1 and HGF can lead to cell cycle arrest of B cells(G0/G1)[93].Additionally,direct cell contact interactions,mostly utilizing the Fas/Fas ligand,TRAIL/DR death signaling,and PD-L1/PD-1 pathways,can promote apoptosis in B cells[94,95].Recent evidence also showed that coculture of MSCs with B cells resulted in downregulation of CXCR4 and CXCR5,thus preventing the migratory ability and homing of B cells towards CXCL12 and CXCL13 chemoattractant agents.It has been shown that BM-MSCsviasecretion of GM-CSF can inhibit the production of CXCR4,CXR5,IL-6,and IL-7 by activated B cells[95].Indeed,the MSC interaction with plasma B cells results in impaired secretion of immunoglobulin (Ig)M,IgG,and IgA by plasma B cells.However,MSCs cannot downregulate the expression of the costimulatory molecules CD80,CD86,and HLA-DR in activated B cells[96].Additionally,MSCs did not cause any negative effect on IFN-γ,TNF-α,IL-4,and IL-10 expression by B cells[96].

    Modulation of NK responses

    A remarkably complex interplay between NK cells and MSCs has been reported[99].Indeed,NK cells can exert cytolytic actions against MSCs due to the low expression of HLA class I[100].Alternatively,activation of MSCs with IFN-γ leads to upregulation of HLA class I expression,which can strongly interact with KIRs,inhibiting in this way the MSCs cytolysis mediated by NK cells[100].In this context,toll-like receptors (TLRs),presented in MSCs,seem to play a significant role.Activation of TLR3 in MSCs leads to increased immunosuppression against NK cells[101].

    Further immunosuppression of NK cells is mediated by the secretion of soluble factors from MSCs[29].Indeed,IDO and PGE2 can inhibit IL-2 induced NK responses,while TGF-β1 and HGF act cooperatively with the above-described molecules[29,102].Depending on the microenvironment stimuli,MSCs can either activate or inhibit the action of NK cells.It has been shown that WJ-MSCs can stimulate the proliferation of NK cellsviathe production of inflammatory cytokines,including TNF-α,IL1α / β,ΙL-6,and others[103].More research is required regarding the interplay of MSCs and NK cells in order to understand better their association.

    HLA-G and immune responses

    The HLA system has an essential key role in immune responses[104].The HLA system includes the HLA class I and class II molecules,which are located within chromosome 6p21[105].In this complex system,the HLA class I involves the classical A,B,and C genes and the non-classical genes E,F,and G,while the HLA class II involves the genes DP,DQ,DM,DO,and DR.Both,HLA class I and II are expressed in all cells,particularly in immune cells,and thus play a significant role in antigen recognition and presentation.On the other hand,the exact role of non-classical HLA genes has not yet been completely elucidated.Among them,HLA-G seems to share key immunoregulatory properties[104,105].

    For the first time,the role of HLA-G was investigated in pregnancy.The placental and fetus region of the umbilical cord express significant amounts of HLA-G,thus preventing the rejection of the semi-allogeneic fetus by the mother[104,106].HLA-G involves the non-secreted membrane bound isoforms HLA-G1-4 and the soluble isoforms HLA-G5-7.It is speculated that HLA-G5 occurs after specific cleavage of membrane-bound HLA-G1 mediated by metalloproteinase-2.It seems that HLA-G exerts its anti-inflammatory and immunoregulatory properties in a wide variety of immune cells,including monocytes,DCs,NK cells,and T cells[104].

    Importantly,the HLA-G isoforms can interact with leukocyte immunoglobulin like receptor B1 (LILRB1,ILT2/CD88j),LIRB2 (ILT4/CD85d),and KIR2DL4 (CD158d),which are expressed in monocytes,DCs,T cells,and NK cells[104,107].Indeed,the interaction of HLA-G with LILRB1 and LIRB2 induces the phosphorylation of the immunoreceptor tyrosine-base inhibitory motifs,followed by activation of SHP phosphatases,which lead to downregulation of MAPK and inhibition of cell proliferation[107].Alongside IDO and IL10,HLA-G can suppress the proliferation of hyperacute T cells and can prevent the differentiation of monocytes to DCs[80,85].In this way,the secreted cytokines,including TNF-α,ΙL1-α,β,IL-6,IL-7,IL-8,IL-9,GM-CSF,and IFN-γ,can be blocked indirectlyviathe HLA-G mediated inhibition of DCs and T cells.In a high inflammatory environment,HLA-G interactions can mediate the recruitment and the expansion of CD4+CD25+FOXP3+T cells (T reg),which in turn can inhibit effectively the proliferation of allocytotoxic T cells.Additionally,soluble HLAG5-7 isoforms,can induce the secretion of IL-10 and TGF-β1,which further promotes the inhibition of CD8+T cell proliferation[104,108].Several reports have indicated that HLA-G can influence the Th2 response,leading to increased production of antiinflammatory cytokine IL-10,TGF-β1,and HGF.HLA-G can also modulate the function of NK cells by interacting with KIR2DL4.It has been described in the literature that endocytosis of soluble HLA-G with KIR2DL4 is required for the inhibition of NK cells and cytokine production[109].On the other hand,it has been reported that HLA-G homodimers are required for the secretion of TNF-α,ΙL-4,and IL-6[110].This specific set of cytokines is required for successful trophoblast implantation.In this way,more experiments must be performed in order to elucidate better the interplay between HLA-G and NK cells.

    MSCs,as part of their immunomodulation,are capable of producing both the membrane bound and soluble HLA-G isoforms.MSCs can be derived efficiently from placental and WJ-tissue,which is located within umbilical cord.Also,it has been shown that placental and WJ-MSCs may exert advanced immunoregulatory/immunosuppressive properties compared to BM or AD -MSCs due to their embryonic origin[106].Evidence from our previous work confirmed the expression of HLA-G isoforms by WJ-MSCs[106].Moreover,HLA-G expression was retained after long term storage of WJ-MSCs with the vitrification approach.Vitrified WJ-MSCs after 1 year of storage at -196 °C successfully inhibited monocyte proliferation in mixed lymphocyte reaction studies[106].In this way,MSCs can be isolated,expanded and stored long term without any negative effect to their immunomodulatory properties.Thus,they can be ready for use on demand.

    MSCS AND COVID-19

    Until date,MSCs have been applied in large scale cell based therapies,where safety and treatment efficacy have been well documented[56].Their unique role in immune modulation led to the use of MSCs as potential treatment in immunological based diseases,including GvHD,MS,ALS,SLE,etc[25,29].Currently,no specific drugs against COVID-19 exist,while the development of satisfactory vaccines is a challenging process.Therefore,a safe and effective treatment is still under investigation.Taking into consideration that SARS-CoV-2 is responsible for an extended immunomodulation,caused by “cytokine storm”,the administration of MSCs may have a considerable therapeutic benefit,especially in patients with increased COVID-19 severity[8,9].In addition,MSCs are negative for ACE2 receptor and TMPRSS2,and thus cannot be a target for SARS-CoV-2,making their application even safer[47].

    Currently,over 30 clinical trials,where MSCs can be potentially applied in COVID-19 as therapeutic agents,have been officially registered (www.clinicaltrials.gov)[111].The majority of the clinical trials involve intravenous administration of MSCs to COVID-19 patients,but most of them are currently under the recruitment phase(Table3 ).

    Among them,a study of Lenget al[47]showed promising results in severe diseased COVID-19 patients.This study was conducted in a great number of hospitals,mostly in China,and was approved by the National Health Commission of China.In this study,clinical grade MSCs were intravenously infused in seven patients diagnosed with SARS-CoV-2.Importantly,one patient was in critical condition and entered the ICU,four patients exhibited severe type of the disease,and the last two were in better condition.Also,a placebo group was used,consisting of three severe type patients.The MSCs were administrated in a number of 1 × 106cells/kg with an infusion rate of 40 drops/min.After 2-4 d of MSC administration,the severe symptoms,including fever,oxygen saturation,and cough,were improved,and the majority of the patients were discharged.Also,the critically severe patients exited the ICU and successfully recovered.On the other hand,one patient from the placebo group was died,one developed ARDS,and one was in stable condition[47].

    Lenget al[47]showed that MSCs exerted their immunoregulatory properties and were capable of tolerating the hyperacute immune responses of patients,thus improving significantly the patients’ overall condition (Figure1).Indeed,the levels of C-reactive protein in the study group were declined,accompanied by a decrease in the TNF-α concentration.Mass cytometry analysis revealed that the overactivated CXCR3+CD4+T cells,CXCR3+CD8+T cells,and CXCR3+NK cells disappeared and that the CD14+CD11c+CD11bmidDCs reversed to normal conditions.Leukopenia was also reversed in all patients within 1 or 2 wk after MSCs administration.Furthermore,the ground glass opacity of lungs seemed to have subsided in patients[47].

    Another important issue that should be mentioned is the time point of MSC administration to COVID-19 patients.The exact time point for MSC administration varied among the studies.In a number of clinical trials,the MSCs are infused at specific time points (0,2,6,10,14 wk) after disease onset.In other studies,MSCs are infused in severe conditioned COVID-19 patients as a co-therapy alongside with theirprimary therapeutic protocol.Severe COVID-19 condition is established through the determination of specific clinical manifestations.Severe clinical manifestations include fever,respiratory distress (respiratory rate ≥ 30/min),low oxygen saturation (≤ 93% at rest state),low arterial partial pressure of oxygen/fraction of inspiration O2 ≤ 300 mmHg,while respiratory failure (connection of patients to extracorporeal membrane oxygenation),shock,and organ failure compromise the critically severe manifestations.The cytokine levels of IL-2,IL-6,IL-7,G-CSF,IP10,MCP1,MIP1A,and TNF-α are also determined and were mostly found to be elevated when patients are suffering from the severe manifestations and critically severe manifestations.

    Table3 Clinical trials associated with the use of mesenchymal stromal cells in coronavirus disease-19

    MSCs can exert their immunoregulatory properties by activating inflammatory cytokines,including IL-1,IL-6,IFN-γ and TNF-α.At disease onset,patients are not characterized by increased alveolar epithelium damage due to the low virus replication.On the other hand,when virus load is high,severe alveolar epithelium damage can occur due to the production of inflammatory cytokines and the initiation of “cytokine storm”.MSCs can now be activated (by inflammatory cytokines),which can lead to immunoregulation of the overactivated immune system.Besides these facts,MSCs could also have a prophylactic effect,and this could be the primary reason for their use at disease onset.Taking into consideration the above data,the specific time point for the administration of MSCs should be established that leads to patients’condition improvement.

    Similar results regarding the immunomodulatory benefits of MSCs have been reported by other research groups around the world.Indeed,in the study of Petrouet al[112]the ALS severity score was decreased in all patients after MSCs infusion,while the treatment was proven safe and well tolerated.

    In this way,MSCs can modulate effectively a series of immune responses,including macrophages,DCs,NK,T,and B cells.Especially in COVID-19,the latest evidence supports that IL-6 is the main inflammatory cytokine for the immune system overactivation,and MSCs may be used as potential immunoregulatory players and inhibitors of IL-6 production[113].MSCs can secrete anti-inflammatory cytokines,including IL-10.In addition,MSCs can induce apoptosis to overactivate T and B cells,promote Th2 responses,and activate M2 macrophages,regulating even more the inflammation.

    Besides its well documented immunoregulatory properties,MSCs may exert key regenerative properties towards damaged alveolar epithelium and lung fibrosis[114].In previous studies,it has been shown that MSCs accumulate in lung capillary vessels after intravenous injections[115].MSCs engraft to the injury site in a chemokine-gradient dependent manner.Upon chemokine detection (CXCL12,SDF-1,CXCL12L),MSCs can upregulate CD44 and ανβ1integrins,and through the interaction with P/E selectins,vascular adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1) can perform the rolling adhesion to endothelium surface until reaching the injury site[25].Then,transendothelial migration of MSCs occurs in a process mediated by junctional adhesion molecules,platelet-EC adhesion molecule-1,and cadherins(Figure2).MSCs produce several growth factors,such as TGF-β1,VEGF,HGF,EGF,and IGF,that could induce the differentiation of alveolar epithelial cells from progenitor cells,attracting the M2 macrophages while reducing the scar tissue formation process[25].This has been further confirmed by evidence regarding the reversion of ground glass opacity in lungs of COVID-19 patients after MSC infusion[47].

    The safe and tolerability of allogeneically infused MSCs have been reported in the past.There was evidence that intravenously infused MSCs could be accumulated in capillary vessels of lungs,thus raising the possibility of pulmonary embolism occurrence.In a phase I clinical trial performed by Iacobaeuset al[115],no long-term engraftment of MSCs was performed in patients with MS.MSCs were further cleared from the circulation through the secondary lymphoid organs[115].In another phase I clinical trial evaluating the possible treatment of ARDS,allogeneic BM-MSCs were well tolerated by the patients,and no infusion or treatment related adverse events were reported[116].Moreover,Matthayet al[117]reported that intravenous injection of MSCs in a number of 10 × 106cells/kg was safe in patients with moderate ARDS.In both studies,after MSC infusion,the levels of IL-6 and IL-8 and the in-hospital mortality of patients were critically decreased,promoting even more the therapeutic potential of MSCs[47,117].In recent years,AD-MSCs have gained significant interest by the scientific society for their regenerative and immunoregulatory properties.Recently,Gentileet al[26,27]reported that AD-MSCs exert key immunosuppressive propertiesviathe secretion of TGF-β1,HGF,and IFN-γ and remarkable regenerative properties through the secretion of VEGF and PDGF[26,27].Indeed,besides their immunosuppressive properties,AD-MSCs can secrete pro-angiogenic factors such as VEGF and PDGF,which can stimulate the ECs,promoting in this way the vascularization and the regeneration of damaged lung tissue[26-28].Moreover,a phase I clinical trial using autologous or allogenic AD-MSCs was conducted since April 2020 in COVID-19 patients,determining the safety and tolerability of these cells[26].

    Moreover,MSCs,upon environmental stimuli,are able to secrete EVs containing biomolecules,which effectively can promote key function processes,such as local immunomodulation and tissue regeneration[118].EVs are composed of lipid bilayer membranes and can be classified into exosomes (microvesicles (MVs) with diameter of 30-100 nm),apoptotic bodies,and the recently described nanovesicles with diameter of 8-12 nm[119,120].MVs mostly contain mRNAs,microRNAs,cytokines,and chemokines that can regulate a wide number of biological processes,including the function and homing of immune cells[121,122].It has been shown that MVs derived from BM-MSCs suppress the expression of IL-1β and TNF-α and can promote the conversion of Th1 to Th2 responses[120,123].Also,MVs contain the miRNAs miR-145,miR-146,and miR-155,which can effectively suppress the expression of TNF receptor-associated factor 6 and IL-1 receptor-associated kinase 1,followed by down-regulation of NF-κB p65 phosphorylation[120,122,124].These events further lead to the impaired production of TNFα,ΙL-1β,and IL-6 and is accompanied by inhibition of proliferation of M1 macrophages[120,122].To date,a clinical trial that involves the application of inhaled exosomes derived from MSCs in patients with COVID-19 has been registered(NCT04276987).Moreover,MSC derived exosomes have been used as therapeutic agents in lung inflammatory diseases and tissue protection from fibrosis.In this context,WJ-MSCs derived exosomes significantly suppressed TGF-β1 expression and its downstream signaling pathway involving the inactivation of SMAD4 and SMAD5,leading to decreased collagen production and attenuation of scar tissue formation[120,125].Exosomes can be produced under large scale good manufacturing practices (GMPs) conditions and could act beneficially in COVID-19 patients.

    Figure2 Transendothelial migration of intravenously infused MSCs in COVID-19 patients.Proposed mechanism of MSCs trafficking towards to chemokine stimuli produced from affected cells.MSCs perform endothelial rolling through interactions of CD44 and ανβ1 with intercellular cell adhesion molecule and vascular cell adhesion molecule.Transendothelial migration of MSCs is mediated through interactions of junctional adhesion molecular,platelet endothelial cell adhesion molecule PECAM,and cadherins.Upon arrival to their destination,MSCs exert their immunomodulatory and regenerative potential to the damaged tissue.COVID-19:Coronavirus disease-19;ICAM:Intercellular cell adhesion molecule;MSCs:Mesenchymal stromal cells;VCAM:Vascular cell adhesion molecule;PECAM:Platelet endothelial cell adhesion molecule;JAM:Junctional adhesion molecular;ECs:Endothelial cells.

    CURRENT LEGISLATION DESCRIBING THE USE OF MSCS

    The use of MSCs in COVID-19 patients is categorized as stem cell-based therapies,and therefore the guidelines of International Society for Stem Cell Research must be strictly followed[126].Moreover,International Society for Stem Cell Research released the “The Guidelines for the Clinical Translation of Stem Cells”,which involves the current standards for the development of stem cell-based therapies,leading to proven therapeutic potential for the patient[126].

    To promote the therapeutic outcome for the patients,MSC based therapies must overcome a great number of challenges,including expansion time,required cell number-dosage,cell cultivation,and cell exposure to animal-derived products,which can affect significantly the safety and efficacy.Furthermore,prolongedin vitrocultured stem cells may lose their key function characteristics such as stemness and plasticity,or even more could undergo malignant tumorigenic transformation[126].

    According to the “Guidance of Human Somatic Cell therapy and Gene Therapy”established for human cells,tissues,and cellular,tissue-based products (HCT/Ps),stem cell-based products must be developed under GMPs conditions.Also,additional regulations exist depending on the cell manipulation or either if HCT/Ps are intended to be used in homologous or allogeneic setting[126].FDA has defined the minimal manipulation as the process,which is not altering the biological characteristics of stem cells.Moreover,processes including density-gradient separation,cell selection,centrifugation,and cryopreservation are defined as minimal manipulation HCT/Ps[126].

    All other processes involving cell cultivation,expansion,exposure to animal derived substances,activation,and gene modifications are considered as more-than-minimalmanipulated HCT/Ps[126].Furthermore,the use of MSCs in allogeneic setting must fulfill donor eligibility (donor screening and testing for communicable diseases),Quality Assurance program (GMPs conditions and Quality Control system),proper storage conditions (long-term stem cell stability under cryopreserved conditions),and distributing–release criteria.The aforementioned information must be specifically defined in Standard Operation Procedure documentation in order to reduce the risk occurrence for the patient.Trials regarding the homologous or allogeneic use of MSCs must be approved by the corresponding national health commission[126].

    All MSC based therapies performed in United States must be registered to the FDA.Accordingly,the European Medicines Agency and the Therapeutic Goods Administration is responsible for the cell-based therapies performed in Europe and in Australia,respectively.According to Committee for Advanced Therapies,which has been established by the European Medicines Agency,all MSC-based products in the European Union will be defined as Advanced Therapeutical Medicinal Products,with the only exception being the aforementioned minimally manipulated stem cells[126].The above requirements and the developed authorities make the MSC based therapies even safer for the patients,bringing stem cell based therapy one step closer to broad clinical utility.

    CONCLUDING REMARKS

    The above evidence clearly indicate that MSCs could be used as potential therapeutic agents in patients suffering from COVID-19.MSCs can modulate effectively the overactivated immune responses caused by SARS-CoV-2 through inactivation of macrophages and NK,T,and B cells,while at the same time could promote the Th2 response and the activation of M2 macrophages[25,29].In addition,MSCs could have a beneficial regenerative effect in damaged lungs and alveolar epithelial cells,reversing in this way the ground glass opacity in patient’s lungs[67].

    Until now,several treatment protocols have been proposed,such as the administration of remdesivir,hydrochoriquine,colchicine,and vaccination of high risk patients[20,22].However,most of these treatments are accompanied by significant adverse reactions,limiting their application to patients.The induced “cytokine storm”by SARS-CoV-2 infection has attracted the attention of the scientific society.This phenomenon,and specifically IL-6,may be responsible for the immune system overactivation and also is associated with poor prognosis in critically ill patients.

    On the other hand,MSCs,which are negative for ACE2 receptor and TMPRSS2,could be effective in regulating the “cytokine storm”[47].Moreover,WJ-MSCs may possess better immunoregulatory properties through the elevated expression of HLAG,the existence of longer telomeres,and fewer epigenetic modifications compared to MSCs from the other sources[106].AD-MSCs that are extensively used in a great series of personalized regenerative medicine applications,including breast reconstruction with fat graft,androgenic alopecia,etc,exhibited similar properties as the MSCs from other sources[127-133].

    Recently,the application of AD-MSCs as immunoregulatory agents in COVID-19 patients is gaining day by day more attention by the scientific society,worldwide[26,27].AD-MSCs can be efficiently isolated in great quantities from SVF or subcutaneous AT,expanded under clinical grade GMP conditions,and applied through intravenously infusion to critically-ill COVID-19 patients[26,27].AD-MSCs exert equal immunoregulatory properties as MSCs from BM and WJ tissue through secretion of soluble factors or cell–cell contact interactions,as has been described previously[26,27].Furthermore,AD-MSCs can be efficiently differentiated towards “chondrogenic” and“osteogenic” lineages and can produce significant amounts of proangiogenic factors,indicating their significant regenerative potential[26,27,127].These regenerative properties of AD-MSCs may prove to be of great importance in restoration of lung alveolar epithelium and reversion of ground-glass opacity in critically-ill COVID-19 patients.Taking into account the above data,AD-MSCs may also represent a safe and effective therapeutic strategy for COVID-19 patients,and may be the best cellular population option when a great number of MSCs are required for immediate use.

    CONCLUSION

    MSCs can be potentially applied in COVID-19 as co-therapy without having severe adverse reactions.The exact time point of MSCs administration should be established in order to obtain the best outcome for patients[134].It has been shown in literature that MSCs can suppress the overactivated immune system of severe and critically severe patients.Simultaneously,MSCs may also possess a prophylactic effect if used at disease onset.Existing evidence suggest that MSCs are important immunoregulatory players,but more research is needed,in order to obtain safer conclusions.The ultimate goal will be to decrease the COVID-19 mortality rate,and this is where MSCs can assist significantly.

    猜你喜歡
    裁量知識產權
    關于江蘇省安全生產行政處罰自由裁量中裁量因子的適用探索
    盜竊罪中罰金刑裁量規(guī)則研究
    南大法學(2021年4期)2021-03-23 07:56:04
    論行政自由裁量的“解釋性控權”
    法律方法(2021年4期)2021-03-16 05:35:16
    應如何確定行政處罰裁量基準
    勞動保護(2018年8期)2018-09-12 01:16:12
    關于稅務行政處罰裁量基準的比較建議
    遼寧經濟(2017年12期)2018-01-19 02:34:00
    重慶五大舉措打造知識產權強市
    關于知識產權損害賠償?shù)膸c思考
    知識產權(2016年5期)2016-12-01 06:58:32
    “加強知識產權保護運用加快知識產權強國建設”-2016年福建省知識產權宣傳周成功開幕
    知識產權為“互聯(lián)網+”護航
    知識產權
    江蘇年鑒(2014年0期)2014-03-11 17:09:48
    av专区在线播放| 高清视频免费观看一区二区 | 欧美一区二区亚洲| 欧美精品国产亚洲| 美女大奶头视频| 亚洲精品自拍成人| 亚洲av一区综合| 26uuu在线亚洲综合色| 人妻夜夜爽99麻豆av| 熟妇人妻久久中文字幕3abv| 日韩电影二区| 晚上一个人看的免费电影| 极品教师在线视频| 最近2019中文字幕mv第一页| 在线观看人妻少妇| 国产成人精品一,二区| av黄色大香蕉| 国产精品蜜桃在线观看| 国产v大片淫在线免费观看| 国产精品久久久久久久久免| 欧美3d第一页| 国产黄片视频在线免费观看| 国产麻豆成人av免费视频| 三级毛片av免费| 国产精品嫩草影院av在线观看| 男女视频在线观看网站免费| 99九九线精品视频在线观看视频| 亚洲怡红院男人天堂| 99久久精品热视频| 2018国产大陆天天弄谢| 91久久精品国产一区二区成人| 色吧在线观看| 麻豆国产97在线/欧美| 女人十人毛片免费观看3o分钟| 插阴视频在线观看视频| 亚洲精品日本国产第一区| av卡一久久| 韩国av在线不卡| 午夜精品国产一区二区电影 | 天美传媒精品一区二区| 免费大片18禁| 夫妻午夜视频| 亚洲一级一片aⅴ在线观看| a级毛片免费高清观看在线播放| 有码 亚洲区| 亚洲欧美日韩卡通动漫| 亚洲精品成人av观看孕妇| 在线观看人妻少妇| 噜噜噜噜噜久久久久久91| 久久人人爽人人爽人人片va| 六月丁香七月| av女优亚洲男人天堂| 国产黄片视频在线免费观看| 午夜激情久久久久久久| 午夜日本视频在线| 国产精品一区二区三区四区久久| 亚洲国产精品成人综合色| 国产精品久久视频播放| 国产精品伦人一区二区| 在线观看免费高清a一片| 日本免费a在线| 国内精品宾馆在线| av卡一久久| 美女黄网站色视频| 一级毛片久久久久久久久女| 男人爽女人下面视频在线观看| 亚洲av不卡在线观看| 狠狠精品人妻久久久久久综合| 国产精品伦人一区二区| 波多野结衣巨乳人妻| 亚洲av日韩在线播放| 男人舔女人下体高潮全视频| 有码 亚洲区| 精品午夜福利在线看| 一夜夜www| av在线蜜桃| 国产一区二区三区av在线| 五月伊人婷婷丁香| 亚洲精品aⅴ在线观看| 国内精品美女久久久久久| 国产老妇女一区| 国产精品精品国产色婷婷| 日本免费a在线| 三级毛片av免费| 51国产日韩欧美| 久久精品国产鲁丝片午夜精品| 性色avwww在线观看| 精品一区二区三区视频在线| 亚洲不卡免费看| 搞女人的毛片| 国内精品美女久久久久久| 哪个播放器可以免费观看大片| 最近最新中文字幕免费大全7| 十八禁网站网址无遮挡 | av线在线观看网站| 99久久精品一区二区三区| 国产探花极品一区二区| 大话2 男鬼变身卡| 精品国产一区二区三区久久久樱花 | 身体一侧抽搐| 高清日韩中文字幕在线| 久久韩国三级中文字幕| 麻豆av噜噜一区二区三区| 国产探花在线观看一区二区| 在线a可以看的网站| 精品一区二区三区人妻视频| 欧美日韩在线观看h| 亚洲国产欧美人成| 国产精品嫩草影院av在线观看| 免费看日本二区| 麻豆精品久久久久久蜜桃| 久久草成人影院| 成年女人在线观看亚洲视频 | av在线亚洲专区| 国内少妇人妻偷人精品xxx网站| 亚洲国产欧美在线一区| 国产成人a∨麻豆精品| 欧美xxxx性猛交bbbb| 国产精品国产三级国产专区5o| 天堂网av新在线| 一个人看视频在线观看www免费| 夜夜看夜夜爽夜夜摸| 亚洲欧美日韩无卡精品| or卡值多少钱| 午夜激情福利司机影院| 亚洲av中文字字幕乱码综合| 国产av码专区亚洲av| 九九久久精品国产亚洲av麻豆| 欧美性感艳星| 午夜激情福利司机影院| 欧美高清成人免费视频www| 中文天堂在线官网| 97超视频在线观看视频| 18禁裸乳无遮挡免费网站照片| 国产视频内射| 99re6热这里在线精品视频| 国产一区二区三区av在线| 最近中文字幕高清免费大全6| 国产v大片淫在线免费观看| 黄色配什么色好看| 26uuu在线亚洲综合色| 超碰av人人做人人爽久久| 两个人视频免费观看高清| 麻豆av噜噜一区二区三区| 亚洲三级黄色毛片| 寂寞人妻少妇视频99o| av又黄又爽大尺度在线免费看| 国产亚洲av嫩草精品影院| 免费黄频网站在线观看国产| 国产成人精品久久久久久| 精品午夜福利在线看| 五月天丁香电影| 别揉我奶头 嗯啊视频| 国产午夜精品论理片| 欧美激情国产日韩精品一区| 日韩av在线免费看完整版不卡| 九色成人免费人妻av| 性色avwww在线观看| 亚洲国产精品国产精品| 欧美激情久久久久久爽电影| 国产午夜福利久久久久久| 亚洲欧美精品自产自拍| 97人妻精品一区二区三区麻豆| 一级片'在线观看视频| 亚洲精品影视一区二区三区av| 亚洲国产最新在线播放| 91精品伊人久久大香线蕉| 性插视频无遮挡在线免费观看| 日韩 亚洲 欧美在线| 亚洲不卡免费看| 免费大片黄手机在线观看| 天天一区二区日本电影三级| 亚洲第一区二区三区不卡| 自拍偷自拍亚洲精品老妇| 五月玫瑰六月丁香| 日本免费a在线| 插阴视频在线观看视频| 亚洲成人一二三区av| 午夜福利成人在线免费观看| 一级毛片aaaaaa免费看小| 欧美变态另类bdsm刘玥| 国产精品.久久久| 神马国产精品三级电影在线观看| 亚洲精品日韩av片在线观看| 精品国产三级普通话版| 九九久久精品国产亚洲av麻豆| 丝袜美腿在线中文| 国产精品久久久久久av不卡| 亚洲最大成人手机在线| 内地一区二区视频在线| 日韩国内少妇激情av| 深夜a级毛片| 深爱激情五月婷婷| 亚洲综合精品二区| 最近2019中文字幕mv第一页| 亚洲av不卡在线观看| 亚洲天堂国产精品一区在线| 色视频www国产| 国产精品人妻久久久久久| 91午夜精品亚洲一区二区三区| 精品久久久久久久久av| 秋霞在线观看毛片| 久久久久久久久久成人| 国产精品无大码| 国产黄色小视频在线观看| 久久人人爽人人片av| 欧美日本视频| 91久久精品电影网| 久久久久久久久大av| 国产免费视频播放在线视频 | 免费观看av网站的网址| 日韩欧美三级三区| 一本久久精品| 国产大屁股一区二区在线视频| 99久久九九国产精品国产免费| 五月伊人婷婷丁香| 免费观看性生交大片5| 嘟嘟电影网在线观看| 日韩国内少妇激情av| 国产午夜精品久久久久久一区二区三区| 91久久精品国产一区二区三区| 午夜爱爱视频在线播放| .国产精品久久| 欧美另类一区| 久久久久久久亚洲中文字幕| 婷婷六月久久综合丁香| 国产人妻一区二区三区在| 黄色一级大片看看| 亚洲欧洲日产国产| 九九爱精品视频在线观看| 国产精品综合久久久久久久免费| 亚洲欧美清纯卡通| 国产精品一区二区三区四区免费观看| 国产精品爽爽va在线观看网站| 亚洲av在线观看美女高潮| 男人舔奶头视频| 美女内射精品一级片tv| 免费av观看视频| 亚洲伊人久久精品综合| 成人亚洲精品av一区二区| 中文天堂在线官网| 2021少妇久久久久久久久久久| 少妇熟女aⅴ在线视频| 麻豆国产97在线/欧美| 日本三级黄在线观看| 国产极品天堂在线| 麻豆成人午夜福利视频| 人人妻人人澡人人爽人人夜夜 | 十八禁国产超污无遮挡网站| 热99在线观看视频| 97精品久久久久久久久久精品| a级一级毛片免费在线观看| 你懂的网址亚洲精品在线观看| 午夜福利高清视频| 亚洲av福利一区| 六月丁香七月| 国产乱人偷精品视频| 免费大片黄手机在线观看| 我的女老师完整版在线观看| 亚洲欧美一区二区三区国产| 国产欧美日韩精品一区二区| 国产高潮美女av| 亚洲欧美成人综合另类久久久| 久久6这里有精品| 亚洲久久久久久中文字幕| 成人亚洲精品一区在线观看 | 2018国产大陆天天弄谢| 日本av手机在线免费观看| 亚洲国产色片| 一级毛片aaaaaa免费看小| 日本与韩国留学比较| 一级二级三级毛片免费看| 嘟嘟电影网在线观看| av福利片在线观看| 欧美精品国产亚洲| 日韩亚洲欧美综合| 日韩欧美一区视频在线观看 | 高清日韩中文字幕在线| 在线免费十八禁| 久久久久久久久中文| av国产免费在线观看| 一区二区三区免费毛片| 亚洲av成人精品一区久久| 国产精品国产三级专区第一集| 久久久国产一区二区| 99久国产av精品| 在线观看av片永久免费下载| 精品欧美国产一区二区三| 天天一区二区日本电影三级| 少妇裸体淫交视频免费看高清| 一级毛片aaaaaa免费看小| 亚洲av.av天堂| 久久草成人影院| freevideosex欧美| 亚洲人与动物交配视频| 成人毛片60女人毛片免费| 18禁在线无遮挡免费观看视频| 特级一级黄色大片| 久久精品综合一区二区三区| 精品国内亚洲2022精品成人| 中文精品一卡2卡3卡4更新| 久热久热在线精品观看| 亚洲精品日韩av片在线观看| 又爽又黄无遮挡网站| 亚洲精品乱码久久久久久按摩| 午夜精品在线福利| 亚洲欧美精品自产自拍| 99久国产av精品国产电影| h日本视频在线播放| 亚洲精品久久午夜乱码| 亚洲,欧美,日韩| 亚洲精品国产成人久久av| 国产成人精品一,二区| 亚洲国产精品专区欧美| 久久精品国产亚洲av天美| 欧美日韩在线观看h| 一级黄片播放器| 午夜福利高清视频| 能在线免费观看的黄片| 91久久精品电影网| 能在线免费观看的黄片| 男的添女的下面高潮视频| 2021少妇久久久久久久久久久| 三级男女做爰猛烈吃奶摸视频| 91在线精品国自产拍蜜月| 尾随美女入室| 美女xxoo啪啪120秒动态图| 午夜免费观看性视频| 国产男人的电影天堂91| 青春草视频在线免费观看| 久久久久久久久久黄片| 国产亚洲av片在线观看秒播厂 | 欧美xxxx性猛交bbbb| 亚洲欧美精品自产自拍| 亚洲精品日本国产第一区| 一级毛片黄色毛片免费观看视频| 国产精品久久视频播放| 最近中文字幕2019免费版| 国产成人a∨麻豆精品| 九草在线视频观看| 午夜福利视频精品| 老司机影院毛片| 国产精品久久久久久av不卡| 国产精品1区2区在线观看.| 黄片wwwwww| 国产麻豆成人av免费视频| 日本-黄色视频高清免费观看| 久久午夜福利片| 国产午夜精品论理片| 舔av片在线| 国产精品人妻久久久久久| 一级毛片电影观看| 亚洲欧美成人精品一区二区| 亚洲av电影在线观看一区二区三区 | 免费黄频网站在线观看国产| 国产精品人妻久久久影院| 真实男女啪啪啪动态图| 国产亚洲91精品色在线| 日韩欧美一区视频在线观看 | 岛国毛片在线播放| 国产精品久久久久久av不卡| 国产男女超爽视频在线观看| 国产在视频线精品| 精品熟女少妇av免费看| 国内精品宾馆在线| 永久免费av网站大全| 日本欧美国产在线视频| 国产精品综合久久久久久久免费| 97精品久久久久久久久久精品| 日韩av在线免费看完整版不卡| 最近2019中文字幕mv第一页| 亚洲真实伦在线观看| 人妻少妇偷人精品九色| 午夜日本视频在线| 三级国产精品片| 免费高清在线观看视频在线观看| 婷婷色av中文字幕| 少妇丰满av| 亚洲美女搞黄在线观看| 我的女老师完整版在线观看| 日韩视频在线欧美| 丰满乱子伦码专区| 久久久久免费精品人妻一区二区| 一夜夜www| 九草在线视频观看| 成人无遮挡网站| 在线天堂最新版资源| 亚洲欧美清纯卡通| 一区二区三区高清视频在线| 韩国av在线不卡| 国产精品国产三级专区第一集| 三级国产精品片| 黄片无遮挡物在线观看| 久久久久久久国产电影| 久久久久久久久大av| 久久久a久久爽久久v久久| 在线免费观看的www视频| 国产一区有黄有色的免费视频 | 直男gayav资源| 久久久成人免费电影| 老师上课跳d突然被开到最大视频| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 赤兔流量卡办理| 国产精品爽爽va在线观看网站| 中文资源天堂在线| 成人午夜高清在线视频| 精品不卡国产一区二区三区| 中文乱码字字幕精品一区二区三区 | 嫩草影院入口| 欧美日韩一区二区视频在线观看视频在线 | av在线播放精品| 熟妇人妻久久中文字幕3abv| 欧美成人a在线观看| 国产男女超爽视频在线观看| 老司机影院成人| av网站免费在线观看视频 | 日本黄大片高清| 国产人妻一区二区三区在| 日韩一本色道免费dvd| 99热这里只有是精品在线观看| 久久国产乱子免费精品| 久久久久久久久久久丰满| 免费电影在线观看免费观看| 青春草视频在线免费观看| 成人特级av手机在线观看| 日韩成人伦理影院| 69av精品久久久久久| 久久久久久久久久人人人人人人| 好男人视频免费观看在线| 精品熟女少妇av免费看| 午夜激情福利司机影院| 精华霜和精华液先用哪个| 久久精品国产亚洲av天美| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 中文资源天堂在线| 少妇猛男粗大的猛烈进出视频 | 亚洲精品乱久久久久久| 亚洲av中文字字幕乱码综合| 久久久久久伊人网av| 精品久久久久久成人av| 黑人高潮一二区| 亚洲av中文字字幕乱码综合| 久久99热这里只频精品6学生| 网址你懂的国产日韩在线| 一本久久精品| 亚洲精品亚洲一区二区| 99热全是精品| 热99在线观看视频| 中文字幕久久专区| 欧美一区二区亚洲| 精品酒店卫生间| 春色校园在线视频观看| 亚洲av中文av极速乱| 国产精品久久久久久久久免| 免费播放大片免费观看视频在线观看| 欧美成人精品欧美一级黄| 免费看a级黄色片| 欧美极品一区二区三区四区| 深夜a级毛片| 亚洲四区av| 黄色一级大片看看| 亚洲精品日韩在线中文字幕| 99九九线精品视频在线观看视频| 97超碰精品成人国产| 成人漫画全彩无遮挡| 亚洲,欧美,日韩| 在线观看美女被高潮喷水网站| 麻豆成人av视频| 99九九线精品视频在线观看视频| 天堂av国产一区二区熟女人妻| 中文精品一卡2卡3卡4更新| 真实男女啪啪啪动态图| 亚洲18禁久久av| 美女被艹到高潮喷水动态| 精品一区在线观看国产| 人人妻人人看人人澡| 淫秽高清视频在线观看| 91精品一卡2卡3卡4卡| 最近视频中文字幕2019在线8| 国产欧美日韩精品一区二区| 又粗又硬又长又爽又黄的视频| 日韩电影二区| 丰满乱子伦码专区| 国产亚洲精品av在线| 国产精品精品国产色婷婷| 尾随美女入室| 在线观看美女被高潮喷水网站| 精品亚洲乱码少妇综合久久| 免费av毛片视频| 伊人久久国产一区二区| 日日撸夜夜添| 夜夜爽夜夜爽视频| 久久人人爽人人爽人人片va| 啦啦啦韩国在线观看视频| 夫妻午夜视频| 亚洲丝袜综合中文字幕| 日韩欧美三级三区| 亚洲精品一区蜜桃| 亚州av有码| 精品一区二区三卡| 国国产精品蜜臀av免费| 久久久精品免费免费高清| 精品久久国产蜜桃| 国产成人午夜福利电影在线观看| av在线天堂中文字幕| 亚洲,欧美,日韩| 一级毛片电影观看| 91狼人影院| 日韩伦理黄色片| 能在线免费观看的黄片| 国产乱人视频| 欧美3d第一页| 3wmmmm亚洲av在线观看| 精品久久久久久成人av| 日日撸夜夜添| 亚洲人成网站高清观看| 一级片'在线观看视频| 美女被艹到高潮喷水动态| 丰满乱子伦码专区| 国产伦在线观看视频一区| av在线播放精品| 国产高清不卡午夜福利| 一本一本综合久久| 我的老师免费观看完整版| 能在线免费观看的黄片| 午夜日本视频在线| 免费看日本二区| 亚洲欧美精品专区久久| 久久草成人影院| 日韩不卡一区二区三区视频在线| 亚洲精品乱码久久久v下载方式| 久久精品国产自在天天线| 丝瓜视频免费看黄片| 高清日韩中文字幕在线| 成人综合一区亚洲| 久久久精品94久久精品| 国产亚洲精品av在线| 校园人妻丝袜中文字幕| 国产精品1区2区在线观看.| 亚洲综合精品二区| 国产成人精品久久久久久| 亚洲精品第二区| 亚洲精品,欧美精品| 国产一级毛片在线| 国产真实伦视频高清在线观看| 极品教师在线视频| 亚洲欧美成人综合另类久久久| 亚洲图色成人| 亚洲精品色激情综合| 欧美潮喷喷水| 我要看日韩黄色一级片| 熟妇人妻久久中文字幕3abv| 国产av国产精品国产| 大香蕉久久网| 一区二区三区免费毛片| 肉色欧美久久久久久久蜜桃 | 亚洲aⅴ乱码一区二区在线播放| h日本视频在线播放| 亚洲综合精品二区| 成人毛片60女人毛片免费| 亚洲欧美一区二区三区国产| 亚洲精品久久久久久婷婷小说| 免费看日本二区| 久久精品夜夜夜夜夜久久蜜豆| 国产一区有黄有色的免费视频 | 天堂俺去俺来也www色官网 | 男人和女人高潮做爰伦理| 91午夜精品亚洲一区二区三区| 国内精品宾馆在线| 久久热精品热| 国产精品伦人一区二区| 欧美日韩精品成人综合77777| 亚洲天堂国产精品一区在线| av又黄又爽大尺度在线免费看| 午夜视频国产福利| 日本爱情动作片www.在线观看| 欧美最新免费一区二区三区| 亚洲四区av| 午夜日本视频在线| 婷婷色av中文字幕| 少妇被粗大猛烈的视频| 日本三级黄在线观看| 最近最新中文字幕免费大全7| 精品国内亚洲2022精品成人| 91久久精品国产一区二区三区| 一级毛片aaaaaa免费看小| 最近视频中文字幕2019在线8| 黄色配什么色好看| 久久午夜福利片| 国内精品美女久久久久久| 在线 av 中文字幕| 只有这里有精品99| 99热这里只有精品一区| 亚洲自偷自拍三级| kizo精华| 国产成人a∨麻豆精品| 大话2 男鬼变身卡| 午夜激情福利司机影院| 日本午夜av视频| 极品少妇高潮喷水抽搐| 国产黄a三级三级三级人| 久久久久久久久久成人| 国模一区二区三区四区视频| 中文天堂在线官网| 久久草成人影院| 免费电影在线观看免费观看| 少妇的逼水好多| 免费观看性生交大片5| 在线天堂最新版资源| 亚洲精品第二区| 国内揄拍国产精品人妻在线| 99热这里只有是精品50| 噜噜噜噜噜久久久久久91| 国产精品.久久久| 久久久色成人|